Dr. Alexander Melamed, MD, MPH

Dr. Melamed practices at Wentworth-Douglass Hospital in Dover, New Hampshire, part of Mass General Brigham.

Dr. Melamed's NPI, 1811254154, was assigned on April 11, 2012. Dr. Melamed graduated from University of Southern California Keck School of Medicine in 2012. Dr. Melamed holds Massachusetts license 265570.

Dr. Melamed's primary practice is Wentworth-Douglass Hospital, at 789 Central Ave, Dover, NH 03820 in Strafford County. The practice phone is (603) 740-2580.

Dr. Melamed's primary practice is Wentworth-Douglass Hospital in Dover, New Hampshire, part of Mass General Brigham. Dr. Melamed is also affiliated with Massachusetts General Hospital. The medical group on file is Massachusetts General Physicians Organization (MGPO). Dmand AI also links Dr. Melamed to 1 more hospital, 3 medical groups and 1 therapy and rehab clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Melamed practices, 4 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Melamed's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dmand AI has Dr. Melamed's licenses on file in 3 states: Massachusetts, New Hampshire and New York.

CMS data shows 183 Medicare services from Dr. Melamed across 6 procedure codes in 2024, for 106 Medicare patients. Medicare paid $27,195 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 106 Medicare patients who saw Dr. Melamed in 2024. The largest group is 65 to 74, with 47 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 14% are also on Medicaid. Their average risk score is 1.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Melamed's median patient age at 65, with 99% women.

In 2024, Dr. Melamed wrote 106 Medicare Part D claims for 38 patients. 81% of them were for generic drugs. CMS names the drug for 25 of them, across 1 drug with 11 or more claims each, at $119 in total drug cost. In 2023, CMS named 13 claims across 1 drug.

Dr. Melamed accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Melamed as offering telehealth. CMS counts 22 procedures of removal of the uterus by Dr. Melamed, more than 94% of the clinicians it reports for that procedure.

Dmand AI links 170 papers to Dr. Melamed, published from 2012 to 2025. 2022 was the busiest year, with 24. The most frequent topics are Ovarian Neoplasms, Hysterectomy and Uterine Cervical Neoplasms. Dr. Melamed has published most often in Gynecol Oncol. Dr. Melamed's most frequent co-authors are Jason D. Wright, MD, Allison A. Gockley, MD and June Yijuan Hou, MD.

CMS Open Payments shows 13 general payments to Dr. Melamed from 5 drug and device companies from 2017 to 2023. Consulting fees make up the largest share, 66% of the total. AstraZeneca Pharmaceuticals LP paid the most, $4,394.

Dr. Melamed graduated from University of Southern California Keck School of Medicine in 2012.